Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: hmpa who wrote (2068)	4/4/2004 3:38:18 PM
From: scaram(o)uche	Respond to of 3044

Oooooooh, man, and I was going to throw away that thirty year old Mazola. Next time I find a basal or squamous cell carcinoma (from my wild youth, riding beaches), a little dab will do me. >> And how it could be tracked in a statistically meaningful way on the background of butyrate-rich diet? << Well, if added to the oil for french fries, why not just monitor body load for acrylamide as a tag for butyrate consumed? ;-)

To: hmpa who wrote (2068)	4/4/2004 4:05:03 PM
From: Miljenko Zuanic	Respond to of 3044

OT: Butyric acid by itself is toxic. So, it has to be ester or something that will survive for while until drug is accumulated in "cancer" (yes, right) cells. Pivanex was dead until (two years ago) HDI as approach to adjuvant (or chemo combination) cancer therapy emerged again. With so many new modality I do not think (or hope for) that HDI will have brad application. TTP has nothing better to do, so as long as NCI is helping to pay for trial they are pushing forward. Miljenko